ArticleTargeted oncology2014
Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.
Article in Targeted oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 56 citations in OpenAlex.
- Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications.European journal of nuclear medicine and molecular imaging · 2025Article
- Advancing Cancer Immunotherapy Using Lipid Nanoparticle-Based Approaches.International journal of nanomedicine · 2025Review
- Recent Updates Regarding the Antiproliferative Activity ofLife (Basel, Switzerland) · 2024Article
- Effect of hypoxia-induced mIL15 expression on expansion and memory progenitor stem-like TILsFrontiers in immunology · 2024Article
- Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Contribution of natural killer cells in innate immunity against colorectal cancer.Frontiers in oncology · 2022Review
- Repurposing approved drugs for cancer therapy.British medical bulletin · 2021Review
- Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy.Cancers · 2021Review
- Dendritic cell tracking and modulation.Nature materials · 2020Article
- Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy.Acta pharmaceutica Sinica. B · 2020Review
- Advanced biomaterials for cancer immunotherapy.Acta pharmacologica Sinica · 2020Review
- Rapid, Fatal Acute Right Ventricular Failure After Locoregional Cytokine Therapy for Uveal Melanoma Liver Metastases.Texas Heart Institute journal · 2020Article
- Fueling chimeric antigen receptor T cells with cytokines.American journal of cancer research · 2020Review
- Delivery strategies of cancer immunotherapy: recent advances and future perspectives.Journal of hematology & oncology · 2019Review
- Delivery technologies for cancer immunotherapy.Nature reviews. Drug discovery · 2019Review
- Migration and invasion in B16-F10 mouse melanoma cells are regulated by Nrf2 inhibition during treatment with ionizing radiation.Oncology letters · 2018Article
- Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications.Cellular oncology (Dordrecht, Netherlands) · 2018Review
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.Cell death & disease · 2018Review
- The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy.Frontiers in oncology · 2018Review
- Cytological Assessments and Transcriptome Profiling Demonstrate that Evodiamine Inhibits Growth and Induces Apoptosis in a Renal Carcinoma Cell Line.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared acute toxicity, drug exposure, in-hospital mortality, and inpatient length of stay between two currently recommended dosing protocols (from the National Comprehensive Cancer Network Guidelines) of high-dose interleukin-2 (IL-2) treatment for patients with metastatic melanoma. Patients with metastatic melanoma who received high-dose IL-2 treatment between 2003 and 2010 were identified. Chemotherapy orders, electronic medical records, paper medical charts, and patient discharge summaries were reviewed retrospectively. We identified 13 patients who had received 600,000 units/kilogram (kg)/dose and 15 patients who had received 720,000 units/kg/dose. Patients in the 720,000 units/kg/dose group had a higher rate of grade 3 and 4 bilirubin elevations (34 vs. 12 %), weight gain (any grade, 96 vs. 89 %), and thrombocytopenia (any grade, 75 vs. 65 %). Patients receiving the higher dose also experienced more dose-limiting neurotoxicity (45 vs. 23 %), large-volume diarrhea (15 vs. 0 %), and hepatotoxicity (7 vs. 0 %). There was no in-hospital mortality during treatment in either group. The average length of stay was similar between both groups (5 days, SD = 1 for both groups), and the median cumulative IL-2 exposure was similar between both groups for the first course (10.1 vs.10.5 million units/kg) and for all courses (approximately 11-12 million units/kg). Both high-dose IL-2 protocols had comparable in-hospital mortality and cumulative IL-2 exposure. The 720,000 units/kg/dose dosing scheme did not shorten the length of stay but did lead to greater acute toxicity. Therefore, as a result, we recommend 600,000 units/kg/dose when deciding between the two regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.